| The federal investigation into generic drugmakers' alleged price-fixing should be right in the Trump administration's wheelhouse: a case of almost every major manufacturer of cheap pills colluding to rake in billions of dollars by carving up the market and jacking up prices for medications relied on by Americans. But years after the Justice Department's probe started, not much has happened. A coalition of state attorneys general has laid out voluminous allegations in two lawsuits. But the federal probe—which carries the far-more serious threat of criminal charges—seems to have stalled. The highest price, so far, has been paid by patients. One drug, used to treat obsessive-compulsive disorder, suddenly went up in cost by more than 1,000%. One psychiatrist said she thought about trying to find a veterinarian to prescribe her patient a cheaper version of the pill. That's right—a drug for people went up in price so much that a doctor thought about telling her patient to take medicine made for a dog. There's plenty that's arguably broken with health care in America. But when the basic economics of a system meant to turn expensive brand drugs into cheap generic ones stop working, there are bigger problems.—Drew Armstrong Here's what else we're watching: Mylan's makeover. The EpiPen maker's combination with Pfizer's Upjohn may eventually wipe the Mylan name from pharmacy shelves, but its old boss Robert Coury will keep a very firm grip on the reins. Border patrol. HHS and FDA want to make it easier to import cheaper drugs from Canada, a reversal of sorts for U.S. health agencies as they grapple with surging prices. Drug companies want to maintain a wall. E-scripts skirmish. The future of pharmacies may well be online, and right now, companies hoping to shape that future are duking it out over data. Hovering behind all the drama, unsurprisingly, is Amazon.com. Earnings, earnings, earnings. Gilead Sciences, which is remaking itself under a new CEO, and Amgen, battling Enbrel biosimilars, see better days ahead. Cigna and Humana bucked worries about rising health costs Listen up. Season two of our podcast explored what happens when we hand over our health data to companies and governments. Download it here on Apple devices, and here on Android.  Got this newsletter forwarded to you? Sign up to get it every Thursday by clicking here.
We want to hear from you. If you have feedback, questions or potential story ideas, reach out to me at tannett@bloomberg.net Like Bloomberg's Prognosis? Subscribe to Bloomberg.com. You'll get our unmatched global news coverage and two premium daily newsletters, The Bloomberg Open and The Bloomberg Close, and much, much more. See our limited-time introductory offer. Download the Bloomberg app: It's available for iOS and Android. | 
⋮↠〖*HDvideo~〗 2020 Spycies: Dos espías rebeldes Película Completa En Línea released 2020. story: Vladimir y Hector, dos agentes secretos d...
Post a Comment